← Human Trials & Peer-Reviewed Studies
Effects of insulin detemir and NPH insulin on renal handling of sodium, fluid retention and weight in type 2 diabetic patients
Plain-language guide to PMID 22002075 (2012): open-label randomized controlled trial study of Insulin (regular human) and Insulin Detemir in 2 patients.
Key Facts
- PMID
- 22002075
- Journal
- Diabetologia
- Year
- 2012
- Study type
- Randomized Controlled Trial
- Authors
- Hendriksen KV et al. (4 authors)
- DOI
- 10.1007/s00125-011-2345-8
- Registered trial
- NCT01828970
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Insulin (regular human) and Insulin Detemir, published as a randomized controlled trial.
In type 2 diabetic patients, insulin detemir (B29Lys(ε-tetradecanoyl),desB30 human insulin) induces less weight gain than NPH insulin.
Who Took Part
The abstract describes 2 patients taking part.
PubMed indexes the participants as middle-aged adults and older adults.
In a randomised, open-labelled, two-way crossover study of 24 patients with type 2 diabetes, patients were first treated with NPH insulin or insulin detemir for 8 weeks.
How the Study Was Run
The researchers set it up as a randomized, open-label and crossover study.
Random assignment meant chance, not the researchers, decided who got Insulin (regular human) and who got the comparison, which limits bias.
Being open-label, the Insulin (regular human) study did not mask who received what.
In the crossover set-up each of the patients took both Insulin (regular human) and the comparison in turn, acting as their own control.
A time span of 8 weeks appears in the methods.
Thereafter, they were changed to the other insulin for 8 weeks.
In a third 1 week period, they were changed back to the first insulin.
What Was Measured
PubMed files the paper under topics including Body Composition, Diabetes Mellitus, Type 2, Extracellular Fluid, Fluid Shifts, Glomerular Filtration Rate, Hypoglycemic Agents and Insulin Detemir.
What This Means in Plain Language
The paper is a randomized, open-label and crossover study of Insulin (regular human) and Insulin Detemir in 2 patients over 8 weeks.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2012 (Diabetologia), a journal based in Germany.
More context: the Insulin (regular human) compound page and the Insulin Detemir compound page.
Our Notes on the Compounds
Insulin (regular human): The 51-amino-acid pancreatic hormone that lowers blood glucose; this page covers regular (short-acting) insulin studied in human trials.
Insulin Detemir: A long-acting basal insulin analog sold as Levemir.
NPH Insulin (isophane): An intermediate-acting insulin made by combining insulin with protamine; also called isophane or NPH insulin (Humulin N, Novolin N).
Related Pages
- Insulin (regular human) in the library
- Insulin Detemir in the library
- NPH Insulin (isophane) in the library
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.